Anti-Mouse CD4 (Clone YTS191) – Purified in vivo GOLD™ Functional Grade

Unknown

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Depletion
IHC (Frozen)

Clone YTS191 recognizes an epitope on mouse CD4.

CD4 is expressed on most thymocytes, MHC class II-restricted T cells, a subset of NKT cells, and subsets of dendritic cells and macrophages.

CD4 antibody, clone YTS191, recognizes CD4, a 58 kDa type I transmembrane glycoprotein of the Ig superfamily. CD4 is expressed by the majority of thymocytes, MHC class II-restricted T cells (helper T cells and immunosuppressive regulatory T cells), and subsets of natural killer T (NKT) cells, dendritic cells (DCs) and macrophages^1-3. On T cells, CD4 is a co-receptor of the T cell receptor (TCR) and interacts with major histocompatibility complex (MHC) II molecules on antigen-presenting cells (APCs). CD4 contributes to T cell development and selection and enhances TCR-dependent signaling by up to 100-fold through the accumulation of Lck^4-6. CD4 also contributes to the activation of NKT, macrophages, and DCs^7,8.

1. Krijgsman D, et al. (2018) Front Immunol. 9:367
2. Esashi E, et al. (2003) J Immunol. 171(6):2773-7
3. Vremec D, et al. (2000) J Immunol. 164(6):2978-86
4. Li QJ, et al. (2004) Nat Immunol. 5:791–9
5. Janeway C. A. Jr. (1992) Annu Rev Immunol. 10:645–74
6. Germain RN. (2002) Nat Rev Immunol. 2(5):309-22
7. Thedrez A, et al. (2007) Blood. 110(1):251-8
8. Gibbings D & Befus AD. (2009) J Leukoc Biol. 86(2):251-9